MTIP
CPRX

Magee Thomson Investment Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Magee Thomson Investment Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,197
Closed -$4K – 105
2015
Q4 		$4K Hold
1,197
– – ﹤0.01% 78
2015
Q3 		$4K Buy
1,197
+190
+19% +$820 ﹤0.01% 74
2015
Q2 		$4K Buy
+1,007
New +$4.01K ﹤0.01% 87

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Magee Thomson Investment Partners's CPRX Position: Q1 2016 in Review

Magee Thomson Investment Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2016, closing a stake of 1,197 shares — an estimated $4K sold.

Magee Thomson Investment Partners first reported a position in CPRX in Q2 2015 and held it in 3 quarters. The position peaked at $4K in Q4 2015. 73 funds tracked by Wall St. Rank hold CPRX as of Q1 2016.

  • Magee Thomson Investment Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2016 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 1,197 Catalyst Pharmaceutical shares in Q1 2016, an estimated $4K.
  • Magee Thomson Investment Partners first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 3 quarters.
  • Magee Thomson Investment Partners's Catalyst Pharmaceutical position peaked at $4K in Q4 2015.
  • 73 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2016, filed 20 Apr 2016.